LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company has raised its full-year revenue guidance and EPS, indicating strong financial performance. Despite some management ambiguity on future metrics, the overall sentiment is positive with strategic growth plans, including Artegraft and XenoSure expansion, and a robust sales force strategy. The market cap suggests moderate reaction, predicting a 2-8% stock price increase.
Key Financial Performance
Organic Sales Growth 12% year-over-year growth. Reasons: Higher pricing (10%) and unit growth (2%).
Gross Margin Reported gross margin was 75.3%, adjusted gross margin was 70.8%, a 300 basis point year-over-year increase. Reasons: Higher pricing, manufacturing efficiencies, and product mix.
Operating Income Reported operating income was $20.3 million, adjusted operating income was $16.9 million, up 29% year-over-year. Reasons: Gross margin improvements and operating expense control.
Operating Margin Reported operating margin was 33%, adjusted operating margin was 28%, up from 21% in Q1 and 25% in Q2. Reasons: Operating leverage from gross margin improvements and expense control.
Net Income Reported net income was $17.4 million, adjusted net income was $14.2 million, up 27% year-over-year. Reasons: Gross margin improvements and operating expense control.
Diluted EPS Reported diluted EPS was $0.75, adjusted diluted EPS was $0.62, up 27% year-over-year. Reasons: Gross margin improvements and operating expense control.
Revenue Growth Year-over-year reported revenue growth was 11%. Reasons: Reduced by $1.3 million due to Aziyo distribution exit, benefited by $1 million from weaker U.S. dollar.
Cash and Securities Ended the quarter with $343.1 million, an increase of $23.6 million. Reasons: Generated $28.8 million in cash from operations, paid $4.5 million in dividends.
Adjusted Operating Expenses $26.3 million, an increase of 9% year-over-year. Reasons: Higher compensation expenses and European investments in Ireland, Switzerland, Czechia, and Portugal.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Artegraft: International launch exceeded expectations with Q2 sales of $420,000, Q3 sales of $1.4 million, and expected Q4 sales of $2 million. Artegraft grew 33% worldwide in Q3. Approvals in Canada and Korea expected in 2026.
RestoreFlow: Received German approval in October, with distribution anticipated in Q2 2026. Irish approval expected in H1 2026, which should accelerate other EU approvals.
European Market Expansion: Leased a European RFA distribution facility in Dublin to support launches. Distributed $2.7 million of tissues in the U.K. over the last 12 months.
Price Adjustments: Published 2026 U.S. hospital price list with an 8% increase. 55% of North American revenue now subject to price floors. International price lists are being finalized.
Sales Force Adjustments: Ended Q3 with 152 reps after reducing 8 sales reps based on performance. 23 open rep hiring requisitions with a target of 165 reps by year-end.
New Distribution Center: Opening a 34,000 square foot distribution center near Burlington headquarters in Q1 2026.
Operational Leverage: Achieved adjusted operating margin improvements over the first three quarters of 2025 (21%, 25%, 28%) and guiding 29% in Q4.
FDA Warning Letter: New Jersey Artegraft facility received an FDA warning letter related to quality management system. Written responses provided, and operations remain unaffected.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FDA Warning Letter: The New Jersey Artegraft facility received an FDA warning letter related to the quality management system. While it has not disrupted production, shipping, or invoicing, it represents a regulatory risk that could impact operations if not resolved.
April Recall Impact: The recall led to some customers front-loading catheter purchases into Q2, reducing Q3 organic and unit growth. This indicates potential disruptions in sales patterns and customer purchasing behavior.
Aziyo Distribution Exit: Year-over-year reported revenue growth was reduced by $1.3 million due to the exit from Aziyo distribution, highlighting a challenge in maintaining revenue streams.
European Investments and Expenses: Higher compensation expenses and investments in Ireland, Switzerland, Czechia, and Portugal drove increased operating expenses in H1, which could pressure margins if not offset by revenue growth.
Currency Exchange Impact: The weaker U.S. dollar added $1 million to reported sales, but currency fluctuations remain a risk to financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Artegraft Sales: Q4 2025 sales expected to reach $2 million. Artegraft approvals anticipated in Canada and Korea in 2026.
RestoreFlow Distribution: German approval received in October 2025; distribution to begin in Q2 2026. Irish approval expected in H1 2026, which should accelerate other EU approvals.
European Market Expansion: Leased a European RFA distribution facility in Dublin to support launches. Distributed $2.7 million of tissues in the U.K. over the last 12 months.
Sales Force Expansion: Currently 23 open rep hiring requisitions; expect to have 165 reps by year-end 2025.
2026 U.S. Price List: Published with an 8% increase; 55% of North American revenue now subject to price floors.
New Distribution Center: Opening a 34,000 square foot facility near Burlington headquarters in Q1 2026.
Q4 2025 Operating Income Growth: Guiding 40% operating income growth with a 29% operating margin.
2025 Full Year Revenue Guidance: $248 million, representing 13% growth.
2025 Full Year Adjusted Gross Margin: Expected to be 70.3%.
2025 Full Year Adjusted Operating Income: Guidance of $63.7 million, up 22%, resulting in a 26% adjusted operating margin.
2025 Full Year Adjusted EPS: Guidance of $2.37, an increase of 22% over 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends paid in Q3 2025: $4.5 million in dividends were paid to shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is the company expecting lower organic growth in revenue?
A:The company attributes the lower organic growth to several factors: a catheter recall in Q2 that front-loaded sales into Q2 and pulled them out of Q3 and Q4, struggles in the APAC region due to management turmoil, and a strengthening dollar that reduced Q4 guidance by $600,000 due to FX impact.
Q:What are the moving pieces for gross margin changes through 2026?
A:The company is not ready to guide on 2026 but highlighted progress in gross margin over the last three quarters (69.2% in Q1, 70% in Q2, 70.8% in Q3, and guidance of 71.2% for Q4). Factors include pricing improvements, manufacturing efficiencies, and product mix benefits from products like Artegraft.
Q:How does the company determine the 8% price floor for U.S. hospitals in 2026?
A:The 8% price floor is a blended number across product categories, with some categories achieving higher price increases (e.g., niche products) and others lower (e.g., commodity products like Dacron and ePTFE). The company focuses on niche categories where price hikes are more achievable.
Q:What is the contribution of direct sales in Portugal and Czech Republic this year?
A:The contribution from direct sales in Portugal and Czech Republic is not meaningful so far, as these markets are still very small.
Q:What are the year-to-date price versus volume contributions in various categories?
A:For Q3, the reported basis was 10% price and 2% units. Excluding the catheter recall, it was 11% price and 3% units. For the first nine months of 2025, it was 4.3% units and the balance price. Historical data shows 4% units in 2024 and 5% units in 2023.
Q:What are the key product lines or geographies the company is excited about for 2026?
A:The company is particularly excited about Artegraft, allografts, and XenoSure, with a focus on biologics. European approvals for Artegraft and RFA are expected to drive growth, emphasizing biologics over synthetics or single-use devices.
Q:What is the company's capital deployment strategy with its cash balance?
A:The company has $343 million in gross cash ($170 million net after accounting for convert). While it appreciates the optionality of a higher cash balance, it does not feel pressured to lower acquisition standards. The company is actively pursuing business development and acquisition opportunities.
Q:What is the significance of 55% of North American customers being subject to price floors?
A:The 55% figure indicates the portion of revenue from niche categories where price floors are feasible. The company does not expect this percentage to increase significantly, as the remaining categories are more commodity-like and less suitable for price floors.
Q:How does the company plan to manage increased R&D spending against EPS growth targets?
A:The company expects R&D spending to increase from the current 5-6% of sales to 8-10% over time. This increase will be managed against EPS growth targets, leveraging high operating margins (28-29%) to reinvest in regulatory approvals, factory transitions, and traditional R&D.
Q:What is the potential impact of RestoreFlow approval in Germany?
A:The approval is significant as Germany is the largest medical device market in Europe. However, initial sales are constrained by the need for German-specific inventory from approved recovery centers. Broader European approvals are expected to follow, reducing these constraints.
Q:What is the current size of the sales force, and what are the hiring plans?
A:The company has 152 sales reps with 23 open requisitions, aiming for 165 reps by year-end. The company continues to grow its sales force, particularly in China, where it sees significant long-term potential.
Q:What is driving the strong performance of Artegraft in Europe and South Africa?
A:The strong performance is attributed to the company's well-established European sales channels and unexpected high demand in South Africa, where the dealer has 50-60 reps. Artegraft is being used for peripheral bypasses in Europe and AV access in South Africa.
Q:What are the trends in the cardiac allograft business?
A:The cardiac allograft business is growing faster than the peripheral vascular allograft business, with 56% growth in Q3 for cardiac versus 14% for vascular. Growth is led by the U.K. and Canada, with new management strategies being implemented in the U.S.
Q:What is driving the growth in carotid shunts?
A:The growth (18% in Q3) is primarily due to BARDA exiting the market 1.5-2.5 years ago, leaving the company with high market share and pricing flexibility, especially in Europe.
Q:What are the company's plans for expanding the sales force in China?
A:The company currently has 4 reps in China and is hiring a fifth. It sees significant potential for growth, with the possibility of expanding to 30-100 reps in the long term.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026 gross margins, R&D spending, and the impact of RestoreFlow approval in Germany on 2026 Street numbers. Additionally, they did not provide a clear answer on the mix of new accounts versus higher utilization in existing accounts driving volume growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APAC Price
Burlington headquarters
Dorian
Dublin size
EU market
Ex catheter
Inc Financial
Inventory EU
Korea approval
LeMaitre Vascular
Massachusetts estate
Non measure
President harbor
Price unit
RFA distribution
RJ conference
Shunts EMEA
UK month
approval EU
approval RestoreFlow
approval launch
approval op
benefit line
benefit receipt
benefit tax
cash generation
catheter purchase
center Burlington
country stock
credit Non
credit reconciliation
date risk
day RJ
op income
price list
tax credit
LMAT Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
Positive5-6
The financial performance was robust with significant year-over-year increases in revenue, gross margin, operating income, net income, and EPS. The company also demonstrated strong cash flow from operations. These positive results, coupled with the market cap of a small-cap stock, suggest a strong positive stock price reaction over the next two weeks.
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates strong financial performance with a 20% YoY revenue increase and a transition to net income from a loss. The optimistic guidance for operating income growth and EPS, along with strategic initiatives like sales force expansion and new distribution centers, contribute to a positive outlook. However, the absence of discussions on shareholder returns and potential risks tempers the sentiment slightly. Given the market cap, the stock is likely to see a positive movement (2% to 8%) over the next two weeks.
LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates strong financial performance with a 10% YoY revenue increase, improved margins, and positive net income growth. Strategic initiatives for market expansion and product innovation, along with optimistic revenue and margin projections for 2026, further enhance the outlook. Despite some regulatory risks, the overall sentiment is positive, supported by robust financial metrics and strategic plans. The market cap suggests moderate stock price sensitivity, leading to a positive prediction.
LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript
Positive11-7
The company has raised its full-year revenue guidance and EPS, indicating strong financial performance. Despite some management ambiguity on future metrics, the overall sentiment is positive with strategic growth plans, including Artegraft and XenoSure expansion, and a robust sales force strategy. The market cap suggests moderate reaction, predicting a 2-8% stock price increase.
LMAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
